ProCE Banner Activity

Podcast Pearls: HER2-Positive Breast Cancer: Current Approaches for Quality Care

Slideset Download

Download these slides summarizing key points from a recent podcast with expert discussion on key insights and the most recent data for the management of patients with HER2-positive breast cancer.

Released: September 13, 2022

Expiration: September 12, 2023

No longer available for credit.

Share

Faculty

Erika P. Hamilton

Erika P. Hamilton, MD

Director, Breast Cancer Research Program
Sarah Cannon Research Institute
Tennessee Oncology
Nashville, Tennessee

Komal Jhaveri

Komal Jhaveri, MD, FACP

Associate Attending
Breast Medicine Service and Early Drug Development Service
Section Head, Endocrine Therapy Research Program
Clinical Director, Early Drug Development Service
Department of Medicine
Associate Professor of Medicine
Weill Cornell Medical College
New York, New York

Provided by

Provided by Clinical Care Options, LLC

ProCE Banner

Supporters

Supported by educational grants from

AstraZeneca

Daiichi Sankyo, Inc.

Puma Biotechnology, Inc.

Seagen Inc.

Partners

Smart Patients

ProCE Banner

Faculty Disclosure

Primary Author

Erika P. Hamilton, MD

Director, Breast Cancer Research Program
Sarah Cannon Research Institute
Tennessee Oncology
Nashville, Tennessee

Erika P. Hamilton, MD: consultant (paid to institution): Arcus, Arvinas, AstraZeneca, Black Diamond, Boehringer Ingelheim, CytomX, Daiichi Sankyo, Dantari, Deciphera, Eisai, Greenwich LifeSciences, H3 Biomedicine, iTeos, Janssen, Lilly, Loxo, Merck, Mersana, Novartis, Orum Therapeutics, Pfizer, Puma Biotechnology, Relay Therapeutics, Roche/Genentech, SeaGen, Silverback; researcher (paid to institution): AbbVie, Acerta Pharma, ADC Therapeutics, Akeso, Amgen, Aravive, ArQuIe, Arvinas, AstraZeneca, Atlas Medx, Black Diamond, Boehringer Ingelheim, Clovis, Compugen, Curis, CytomX, Daiichi Sankyo, Dana Farber Cancer Institute, Deciphera, eFFECTOR Therapeutics, Ellipses Pharma, EMD Serono, Fochon, Fujifilm, G1Therapeutics, H3 Biomedicine, Harpoon, Hutchinson MediPharma, Immunogen, Immunomedics, Incyte, InventisBio, Jacobio, Karyopharm, Leap Therapeutics, Lilly, Lycera, MabSpace Biosciences, Macrogenics, Medlmmune, Merck, Mersana, Merus, Millennium, Molecular Templates, Myriad Genetic Laboratories, Novartis, NuCana, Olema, OncoMed, Onconova Therapeutics, ORIC, Orinove, Pfizer, PharmaMar, Pieris, Pionyr Immunotherapeutics, Plexxikon, Radius Health, Regeneron, Repertoire Immune Medicine, Rgenix, Roche/Genentech, SeaGen, Sermonix, Shattuck Labs, Silverback, Stemcentrx, Sutro, Syndax, Syros, Taiho, Taplmmune, Tesaro, Treadwell Therapeutics, Verastem, Vincerx Pharma, Zenith Epigenetics, Zymeworks.

Komal Jhaveri, MD, FACP

Associate Attending
Breast Medicine Service and Early Drug Development Service
Section Head, Endocrine Therapy Research Program
Clinical Director, Early Drug Development Service
Department of Medicine
Associate Professor of Medicine
Weill Cornell Medical College
New York, New York

Komal Jhaveri, MD: consultant: AbbVie, AstraZeneca, Biotheranostics, Blueprint Medicines, Bristol-Myers Squibb, Daiichi Sankyo, Eisai, Genentech, Jounce Therapeutics, Lilly, Novartis, Pfizer, Seattle Genetics, Sun Pharma, Taiho Oncology; researcher (paid to institution): ADC Therapeutics, AstraZeneca, Clovis Oncology, Debio, Genentech, Immunomedics/Gilead, Lilly, Merck/VelosBio, Novartis, Novita Pharmaceuticals, Pfizer, Puma, Zymeworks.